Table 1.
Demographics and baseline characteristics of enrolled participants
| HIV-infected, low CD4 cell count | HIV-infected, high CD4 cell count | HIV-uninfected | |
|---|---|---|---|
| Women | |||
| n | 91 | 89 | 90 |
| Age (years) | 28·0 (18–39) | 28·0 (18–38) | 24·0 (18–39) |
| Black, n (%) | 91 (100%) | 89 (100%) | 90 (100%) |
| Body-mass index (kg/m2) | 26·0 (17·9–48·7) | 24·8 (16·0–43·5) | 25·8 (20·3–43·4) |
| Time from vaccination to delivery (weeks) | 11 (1–19) | 10 (0–18) | 9 (1–17) |
| Gestational age at vaccination (weeks) | 27·0 (22–35) | 29·0 (23–35) | 29·5 (24–34) |
| CD4 cell count at baseline (cells per μL) | 233 (55–348); n=89 | 478 (352–1099) | NA |
| CD4 cell count at delivery (cells per μL) | 262 (30–988); n=81 | 502 (30–1326); n=80 | NA |
| Viral load at baseline (RNA copies per mL) | 2760 (20–814 356); n=90 | 305 (20–334 981); n=88 | NA |
| Viral load at delivery (RNA copies per mL) | 75 (20–240 965); n=80 | 75 (20–729 085); n=81 | NA |
| Baseline HAART, n (%) | 51 (56%) | 47 (53%) | NA |
| Infants | |||
| n | 91 | 88 | 87 |
| Male sex, n (%) | 49 (54%) | 48 (55%) | 46 (53%) |
| Gestational age at birth (weeks) | 39 (27–42) | 38 (29–44) | 39 (29–42) |
| Premature (<37 weeks), n (%) | 19 (21%) | 25 (28%) | 14 (16%) |
| Early premature* (<32 weeks), n (%) | 3 (3%) | 2 (2%) | 1 (1%) |
| Low birthweight (≤2·5 kg), n (%) | 12 (13%)* | 7 (8%)* | 9 (10%) |
Data are presented as the median and range unless stated otherwise and are from the full analysis set. NA=not applicable. HAART=highly active antiretroviral treatment.
*
Two (2%) infants in each group were of very low birthweight (≤1·5 kg).